Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP

Blood (2025) 146 (Supplement 1): 5448.

https://doi.org/10.1182/blood-2025-5448

Published: 2025

Journal Articles

Pre-treatment circulating tumor DNA predicts survival of diffuse large B-cell lymphoma patients and allows genetic and biological evaluation

Blood (2025) 146 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2025-1763

Published: 2025

Journal Articles

Bulky disease and/or very high LDH define a high-risk LBCL subgroup within IPI 1–2, but only in younger patients

Blood (2025) 146 (Supplement 1): 470.

https://doi.org/10.1182/blood-2025-470

Published: 2025

Journal Articles

Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2025-2741

Published: 2025

Journal Articles

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2025-4516

Published: 2025

Journal Articles

Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort

Blood (2025) 146 (Supplement 1): 3676.

https://doi.org/10.1182/blood-2025-3676

Published: 2025

Journal Articles

FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis

Blood (2025) 146 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2025-1826

Published: 2025

Journal Articles

Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

Blood (2025) 146 (Supplement 1): 786.

https://doi.org/10.1182/blood-2025-786

Published: 2025

Journal Articles

Ponatinib-based combination therapies including asciminib and venetoclax were effective on patient-derived xenograft models of chronic myeloid leukemia in blast Phase

Adam Laznicka, Nikola Curik, Jitka Krizkova, Katerina Rajnisova, Pavla Suchankova, Barbora Stefikova, Karyna Zhuk, Vaclava Polivkova, Eva Pokorna, Pavel Klener, Cyril Salek, Hana Klamova, Sarka Ransdorfova, Andreas Hochhaus, Katerina Machova Polakova

Blood (2025) 146 (Supplement 1): 3284.

https://doi.org/10.1182/blood-2025-3284

Published: 2025

Journal Articles

Polatuzumab vedotin induced activation of B-cell receptor signaling creates a synthetic lethality with BTK and AKT inhibition in Mantle Cell Lymphoma

Jana Senavova, Tereza Chrbolkova, Eva Pokorna, Anezka Rajmonova, Vaclav Herman, Karin Ravaszova, Kristyna Kupcova, Pavel Klener, Ondrej Havranek

Blood (2025) 146 (Supplement 1): 3307.

https://doi.org/10.1182/blood-2025-3307

Published: 2025

Journal Articles

Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project

Blood (2025) 146 (Supplement 1): 5299.

https://doi.org/10.1182/blood-2025-5299

Published: 2025

Journal Articles

Improved survival with third-line CAR-T therapy vs alternative treatment in DLBCL: A propensity score–matching analysis

Blood (2025) 146 (Supplement 1): 3664.

https://doi.org/10.1182/blood-2025-3664

Published: 2025

Journal Articles

Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?

Liliana Tuskova, Diana Maláriková, Katerina Benesova, Eva Konirova, Kamila Polgarova, Petra Blahovcova, Jana Salkova, Marek Trněný, Pavel Klener

Blood (2024) 144 (Supplement 1): 3012.

https://doi.org/10.1182/blood-2024-198865

Published: 2024

Journal Articles

Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy

Jana Karolova, Dmitry Kazantsev, Lucie Winkowska, Kristina Forsterova, Liliana Tuskova, Diana Malarikova, Veronika Valkova, Andrea Janikova, Ales Obr, Marek Trneny, Pavel Klener

Blood (2024) 144 (Supplement 1): 2973.

https://doi.org/10.1182/blood-2024-198876

Published: 2024

Journal Articles

Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice

Iva Hamova, Prokop Vodicka, Adriana Velasova, Kristyna Kupcova, Petra Zemankova, Petr Nehasil, Anton Tkachenko, Kamila Polgarova, Jana Salkova, Katerina Benesova, Pavel Klener, Marek Trneny, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 6235.

https://doi.org/10.1182/blood-2024-211263

Published: 2024

Journal Articles

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 230.

https://doi.org/10.1182/blood-2024-209616

Published: 2024

Journal Articles

A Murine Phase 2 Proof-of-Concept Study of Polatuzumab Vedotin in Combination with Venetoclax in Experimental Therapy of BCL2-Positive Aggressive Lymphomas

Dmitry Kazantsev, Eva Pokorna, Kristýna Nožičková, Alexandra Dolníková, Nicol Renešová, Liliana Tuskova, Marek Trněný, Pavel Klener

Blood (2024) 144 (Supplement 1): 974.

https://doi.org/10.1182/blood-2024-194588

Published: 2024

Journal Articles

BMI and Its Changes As a Predictor of Survival in DLBCL Patients

Michal Masar, Prokop Vodicka, Magdalena Klanova, Kamila Polgarova, Katerina Benesova, Diana Malarikova, Jana Salkova, Jan Koren, Pavel Klener, Marek Trneny

Blood (2024) 144 (Supplement 1): 1713.

https://doi.org/10.1182/blood-2024-208542

Published: 2024

Journal Articles

Single Cell RNA Sequencing Enables Identification of Mantle Cell Lymphoma Subclones with Drug-Resistant Profiles Already at Diagnosis and May be Used for Therapy Prognostication and Personalization

Dmitry Kazantsev, Magdalena Klanova, Michal Kolář, Robert Ivánek, Marek Trněný, Pavel Klener, Jr.

Blood (2023) 142 (Supplement 1): 3004.

https://doi.org/10.1182/blood-2023-185925

Published: 2023

Journal Articles

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

Prokop Vodicka, Michal Masar, Magdalena Klanova, Katerina Benesova, Jan Koren, Pavel Klener, Petra Blahovcova, Jitka Dlouha, Sarka Hrabetova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4510.

https://doi.org/10.1182/blood-2023-186467

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP

Pre-treatment circulating tumor DNA predicts survival of diffuse large B-cell lymphoma patients and allows genetic and biological evaluation

Bulky disease and/or very high LDH define a high-risk LBCL subgroup within IPI 1–2, but only in younger patients

Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort

FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis

Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

Ponatinib-based combination therapies including asciminib and venetoclax were effective on patient-derived xenograft models of chronic myeloid leukemia in blast Phase

Polatuzumab vedotin induced activation of B-cell receptor signaling creates a synthetic lethality with BTK and AKT inhibition in Mantle Cell Lymphoma

Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project

Improved survival with third-line CAR-T therapy vs alternative treatment in DLBCL: A propensity score–matching analysis

Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?

Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy

Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

A Murine Phase 2 Proof-of-Concept Study of Polatuzumab Vedotin in Combination with Venetoclax in Experimental Therapy of BCL2-Positive Aggressive Lymphomas

BMI and Its Changes As a Predictor of Survival in DLBCL Patients

Single Cell RNA Sequencing Enables Identification of Mantle Cell Lymphoma Subclones with Drug-Resistant Profiles Already at Diagnosis and May be Used for Therapy Prognostication and Personalization

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only